Trial Profile
Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation With CELLECTRA-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs VGX 3100 (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Proof of concept; Therapeutic Use
- Sponsors Inovio Pharmaceuticals
- 29 Nov 2017 Results of post hoc analysis evaluating biomarker and immunologic data published in an Inovio Pharmaceuticals media release.
- 30 Oct 2017 Results assessing Clinical and Immunological Biomarkers for Histologic Regression of High Grade Cervical Dysplasia, published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 16 May 2017 Results of clinical and immunological biomarkers presented at the IMMUNOLOGY 2017: American Association of Immunologists Annual Meeting